老虎证券

BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial

Reuters
02/03
BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial

Feb 3 (Reuters) - Pfizer Inc PFE.N:

  • PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL

  • PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL

  • PFIZER - STUDY SHOWS 12.3% WEIGHT LOSS AT WEEK 28

  • PFIZER - 10 PHASE 3 TRIALS WITH PF’3944 EXPECTED IN 2026

  • PFIZER - STUDY MET PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT WEIGHT REDUCTION AT 28 WEEKS WITH A COMPETITIVE TOLERABILITY PROFILE

  • PFIZER - PF’3944 MAINTAINS FAVORABLE SAFETY PROFILE THROUGH WEEK 28

  • PFIZER - PLANNING AN EXPANSIVE OBESITY DEVELOPMENT PROGRAM ACROSS ITS PIPELINE, WITH PLANS TO ADVANCE 20+ TRIALS IN 2026

  • PFIZER: ACROSS ARMS 1 AND 3, FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO ADVERSE EVENTS IN WEEKLY PHASE

  • PFIZER: ACROSS ARMS 1 AND 3 FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO AES IN MONTHLY PHASE

Source text: ID:nBw15qHG9a

Further company coverage: PFE.N

((Reuters.Briefs@thomsonreuters.com;))

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10